Anna Dumitriu | |
---|---|
Born | 1969 (age 54–55) [1] |
Nationality | British |
Education | University of Brighton |
Known for | Visual Arts, Bioart |
Notable work | The Romantic Disease, Make Do and Mend, ArchaeaBot: A Post Singularity and Post Climate Change Life-form The Institute of Unnecessary Research Trust me, I'm an artist: towards an ethics of art/science collaboration |
Movement | BioArt |
Anna Dumitriu (born 1969) is a pioneering visual artist based in Brighton, England, specialising in BioArt. Her installations, interventions and performances use digital, biological and traditional media including bacteria, digital technology and craft techniques, working with diverse audiences. [2]
Dumitriu's work is at the forefront of art and science collaborative practice, particularly working with microbiology, infectious diseases, robotics, artificial life technology, and art/science ethics. She was the 2018 President of the Science and the Arts Section of the British Science Association. She is involved in public engagement in science, arts in healthcare and has taught of art/science practice to artists, scientists, art students and medical/science students internationally. She is Artist in Residence with Modernising Medical Microbiology at The University of Oxford, and at the National Collection of Type Cultures at Public Health England. Additionally Dumitriu holds Visiting Research Fellowship: Artist in Residence roles at The University of Hertfordshire in the Biocomputation Group in the School of Computer Science, and in Brighton and Sussex Centre for Global Health Research at Brighton and Sussex Medical School. She was formerly a Visiting Research Fellow: Artist in Residence in the Centre for Computational Neuroscience and Robotics, [3] part of the School of Informatics at Sussex University between 2005 and 2014. She was co-chair of the Arts and Culture Subcommittee of the Alan Turing Centenary. Dumitriu is founder and Director of the Institute of Unnecessary Research and was lead artist on the "Trust me, I'm an artist: towards an ethics of art/science collaboration" project working with the Waag Society in Amsterdam and co-author of the book of the same name. She has written extensively on the notion of the "bacterial sublime".
Her work has an international exhibition profile and has been featured in Frieze, Artforum Wired UK and The Lancet.
Her "Romantic Disease" project explores around historical and contemporary notions of Tuberculosis, whole genome sequencing of bacteria, global health and antimicrobial resistance.
Recent artwork focusses on synthetic biology, antibiotic resistance, and sequencing of bacterial DNA. She created "Make Do and Mend" in 2017 which uses the CRISPR gene editing technique of homologous recombination to edit the genome of E. coli bacteria to remove an antibiotic resistance gene and replace it with the phrase "Make Do and Mend" written into its DNA. The CRISPR Journal described the project as "perhaps the first application of CRISPR gene editing technology in BioArt" and continued "To date, the pioneer in using CRISPR technology for Bio-Art is Anna Dumitriu, a well known British bio-artist. Dumitriu conceived, developed, and exhibited for the first time in 2017 an artwork based on the use of CRISPR at the LifeSpace Gallery for science and art research (Dundee, United Kingdom) as part of the Future Emerging Art and Technology exhibition." [4]
In 2024, the Thackray Museum of Medicine in Leeds hosted a solo exhibition of Dumitriu's work, Fragile Microbiomes, including existing pieces and brand new works. [5]
In January 2014, Dumitriu told The Guardian : "Art, for me, is a way of investigating the world. In that way, I see no real distinction between art and science at all." [6]
An antibiotic is a type of antimicrobial substance active against bacteria. It is the most important type of antibacterial agent for fighting bacterial infections, and antibiotic medications are widely used in the treatment and prevention of such infections. They may either kill or inhibit the growth of bacteria. A limited number of antibiotics also possess antiprotozoal activity. Antibiotics are not effective against viruses such as the ones which cause the common cold or influenza; drugs which inhibit growth of viruses are termed antiviral drugs or antivirals rather than antibiotics. They are also not effective against fungi; drugs which inhibit growth of fungi are called antifungal drugs.
Antimicrobial resistance (AMR) occurs when microbes evolve mechanisms that protect them from the effects of antimicrobials. All classes of microbes can evolve resistance where the drugs are no longer effective. Fungi evolve antifungal resistance, viruses evolve antiviral resistance, protozoa evolve antiprotozoal resistance, and bacteria evolve antibiotic resistance. Together all of these come under the umbrella of antimicrobial resistance. Microbes resistant to multiple antimicrobials are called multidrug resistant (MDR) and are sometimes referred to as superbugs. Although antimicrobial resistance is a naturally occurring process, it is often the result of improper usage of the drugs and management of the infections.
A bacteriophage, also known informally as a phage, is a virus that infects and replicates within bacteria and archaea. The term was derived from "bacteria" and the Greek φαγεῖν, meaning "to devour". Bacteriophages are composed of proteins that encapsulate a DNA or RNA genome, and may have structures that are either simple or elaborate. Their genomes may encode as few as four genes and as many as hundreds of genes. Phages replicate within the bacterium following the injection of their genome into its cytoplasm.
The human microbiome is the aggregate of all microbiota that reside on or within human tissues and biofluids along with the corresponding anatomical sites in which they reside, including the gastrointestinal tract, skin, mammary glands, seminal fluid, uterus, ovarian follicles, lung, saliva, oral mucosa, conjunctiva, and the biliary tract. Types of human microbiota include bacteria, archaea, fungi, protists, and viruses. Though micro-animals can also live on the human body, they are typically excluded from this definition. In the context of genomics, the term human microbiome is sometimes used to refer to the collective genomes of resident microorganisms; however, the term human metagenome has the same meaning.
Antibiotic sensitivity testing or antibiotic susceptibility testing is the measurement of the susceptibility of bacteria to antibiotics. It is used because bacteria may have resistance to some antibiotics. Sensitivity testing results can allow a clinician to change the choice of antibiotics from empiric therapy, which is when an antibiotic is selected based on clinical suspicion about the site of an infection and common causative bacteria, to directed therapy, in which the choice of antibiotic is based on knowledge of the organism and its sensitivities.
Martin J. Blaser is an American physician who is the director of the Center for Advanced Biotechnology and Medicine at Rutgers (NJ) Biomedical and Health Sciences and the Henry Rutgers Chair of the Human Microbiome and Professor of Medicine and Pathology and Laboratory Medicine at the Rutgers Robert Wood Johnson Medical School in New Jersey.
BioArt is an art practice where artists work with biology, live tissues, bacteria, living organisms, and life processes. Using scientific processes and practices such as biology and life science practices, microscopy, and biotechnology the artworks are produced in laboratories, galleries, or artists' studios. The scope of BioArt is a range considered by some artists to be strictly limited to "living forms", while other artists include art that uses the imagery of contemporary medicine and biological research, or require that it address a controversy or blind spot posed by the very character of the life sciences.
The resistome has been used to describe to two similar yet separate concepts:
Hunter Cole is an artist and geneticist. She reinterprets science as art through the creation of living artworks, abstractions, digital art and installations confronting issues related to biotechnology in our culture.
Do-it-yourself biology is a biotechnological social movement in which individuals, communities, and small organizations study biology and life science using the same methods as traditional research institutions. DIY biology is primarily undertaken by individuals with limited research training from academia or corporations, who then mentor and oversee other DIY biologists with little or no formal training. This may be done as a hobby, as a not-for-profit endeavor for community learning and open-science innovation, or for profit, to start a business.
Julian Edmund Davies is a British-born microbiologist and Professor Emeritus in the Department of Microbiology and Immunology at the University of British Columbia.
Jennifer Anne Doudna is an American biochemist who has done pioneering work in CRISPR gene editing, and made other fundamental contributions in biochemistry and genetics. Doudna was one of the first women to share a Nobel in the sciences. She received the 2020 Nobel Prize in Chemistry, with Emmanuelle Charpentier, "for the development of a method for genome editing." She is the Li Ka Shing Chancellor's Chair Professor in the department of chemistry and the department of molecular and cell biology at the University of California, Berkeley. She has been an investigator with the Howard Hughes Medical Institute since 1997.
uBiome, Inc. was a biotechnology company based in San Francisco that developed technology to sequence the human microbiome. Founded in 2012, the company filed for bankruptcy in 2019 following an FBI raid in an investigation over possible insurance fraud involving the US health insurance program Medicare.
Ruth Milne Hall, OAM, FAA, FAAM is an Australian microbiologist whose research on mobile genetic elements in bacteria has provided deep insight into the transfer and evolution of antibiotic resistance in bacteria.
Jo Zayner is a biohacker, artist, and scientist best known for their self-experimentation and work making hands-on genetic engineering accessible to a lay audience, including CRISPR.
Pharmacomicrobiomics, proposed by Prof. Marco Candela for the ERC-2009-StG project call, and publicly coined for the first time in 2010 by Rizkallah et al., is defined as the effect of microbiome variations on drug disposition, action, and toxicity. Pharmacomicrobiomics is concerned with the interaction between xenobiotics, or foreign compounds, and the gut microbiome. It is estimated that over 100 trillion prokaryotes representing more than 1000 species reside in the gut. Within the gut, microbes help modulate developmental, immunological and nutrition host functions. The aggregate genome of microbes extends the metabolic capabilities of humans, allowing them to capture nutrients from diverse sources. Namely, through the secretion of enzymes that assist in the metabolism of chemicals foreign to the body, modification of liver and intestinal enzymes, and modulation of the expression of human metabolic genes, microbes can significantly impact the ingestion of xenobiotics.
The He Jiankui affair is a scientific and bioethical controversy concerning the use of genome editing following its first use on humans by Chinese scientist He Jiankui, who edited the genomes of human embryos in 2018. He became widely known on 26 November 2018 after he announced that he had created the first human genetically edited babies. He was listed in Time magazine's 100 most influential people of 2019. The affair led to ethical and legal controversies, resulting in the indictment of He and two of his collaborators, Zhang Renli and Qin Jinzhou. He eventually received widespread international condemnation.
Locus Biosciences is a clinical-stage pharmaceutical company, founded in 2015 and based in Research Triangle Park, North Carolina. Locus develops phage therapies based on CRISPR–Cas3 gene editing technology, as opposed to the more commonly used CRISPR-Cas9, delivered by engineered bacteriophages. The intended therapeutic targets are antibiotic-resistant bacterial infections.
Abigail A. Salyers was a microbiologist who pioneered the field of human microbiome research. Her work on the bacterial phylum Bacteroidetes and its ecology led to a better understanding of antibiotic resistance and mobile genetic elements. At a time where the prevailing paradigm was focused on E. coli as a model organism, Salyers emphasized the importance of investigating the breadth of microbial diversity. She was one of the first to conceptualize the human body as a microbial ecosystem. Over the course of her 40-year career, she was presented with numerous awards for teaching and research and an honorary degree from ETH Zurich, and served as president of the American Society for Microbiology.
Amy Karle is an American artist, bioartist, and futurist whose work focuses on the relationship between technology and humanity, specifically how technology and biotechnology impact health, humanity, society, evolution, and the future. Karle combines science and technology with art and is known for using living tissue in her work.